|
|||||
|
|
Poor responses to tyrosine kinase inhibitors in a child with precursor B‐cell acute lymphoblastic leukemia with SNX2‐ABL1 chimeric transcript |
|
| Authors: | Aki Masuzawa Chikako Kiyotani Tomoo Osumi Yoko Shioda Kazutoshi Iijima Osamu Tomita Kazuhiko Nakabayashi Keisuke Oboki Kazuki Yasuda Hiromi Sakamoto Hitoshi Ichikawa Kenichiro Hata Teruhiko Yoshida Kenji Matsumoto Nobutaka Kiyokawa Tetsuya Mori |
| Affiliation: | 1. Division of Pediatric Oncology, National Center for Child Health and Development, , Setagaya‐ku, Japan;2. Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, , Setagaya‐ku, Japan;3. Department of Industrial Chemistry, Faculty of Engineering, Tokyo University of Science, , Shinjuku‐ku, Japan;4. Department of Maternal‐Fetal Biology, National Research Institute for Child Health and Development, , Setagaya‐ku, Japan;5. Department of Allergy and Immunology, National Research Institute for Child Health and Development, , Setagaya‐ku, Japan;6. Department of Metabolic Disorder, Diabetes Research Center, National Center for Global Health and Medicine, , Shinjuku‐ku, Japan;7. Division of Genetics, National Cancer Center Research Institute, , Chuo‐ku, Tokyo, Japan |
| Abstract: | In addition to BCR, various rare fusion partners for the ABL1 gene have been reported in leukemia. We have identified the fusion gene SNX2‐ABL1 in a pediatric case of acute lymphoblastic leukemia (ALL), which has only once previously been reported in an adult patient. Cytogenetic analysis detected this fusion gene arising from a t(5;9)(q22;q34) translocation. ALL cells carrying a SNX2‐ABL1 fusion exhibited a BCR‐ABL1+ ALL‐like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib. Treatment using tyrosine kinase inhibitors requires further investigation to optimize the genotype‐based treatment stratification for patients with SNX2‐ABL1 fusion. |
| Keywords: | SNX2‐ABL1 precursor B‐cell acute lymphoblastic leukemia tyrosine kinase inhibitors imatinib dasatinib |